๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Considerations for the development of therapeutic monoclonal antibodies

โœ Scribed by Patrick G Swann; Mate Tolnay; Subramanian Muthukkumar; Marjorie A Shapiro; Barbara L Rellahan; Kathleen A Clouse

Book ID
108099599
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
384 KB
Volume
20
Category
Article
ISSN
0952-7915

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The clinical pharmacology of therapeutic
The clinical pharmacology of therapeutic monoclonal antibodies
โœ Lorin K. Roskos; C. Geoffrey Davis; Gisela M. Schwab ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 176 KB

## Abstract Seventeen monoclonal antibodies are currently approved in the United States for therapeutic use in organ transplantation, percutaneous coronary intervention, prophylaxis of respiratory syncytial virus disease, rheumatoid arthritis, Crohn's disease, asthma, chronic lymphocytic leukemia,

Autoantibody potential of cancer therape
Autoantibody potential of cancer therapeutic monoclonal antibodies
โœ John A. McIntyre; and W. Page Faulk ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 315 KB

## Abstract We and others have reported that multiple autoantibodies are unmasked in human polyclonal antibody preparations after exposure to physiological oxidizing agents (hemin) or electromotive force. We now have asked if oxidation unmasks autoantibody reactivities in monoclonal antibodies (mAb